Shots:

• Celltrion has completed the selection of therapeutic Abs which showed potency for neutralizing the SARS-CoV-2 virus and anticipates cell-line development to initiate this week
• In collaboration with KCDC- Celltrion has identified 300 different types of Abs targeting SARS-CoV-2 antigen. Following the screening process- the company has captured 38 Abs- out of which 14 demonstrated powerful neutralizing antibodies against SARS-CoV-2
• The company anticipates its first clinical study targeting COVID-19 in July and plans to develop a super-Ab or an Ab cocktail therapy targeting the mutations of SARS-CoV-2 along with the anticipated launch of rapid self-testing diagnostic kit in the summer of this year

Click here to­ read full press release/ article | Ref: Celltrion | Image: Celltrion